[go: up one dir, main page]

MX2023012605A - Acidos nucleicos modificados con glicano, metodos de preparacion y usos terapeuticos. - Google Patents

Acidos nucleicos modificados con glicano, metodos de preparacion y usos terapeuticos.

Info

Publication number
MX2023012605A
MX2023012605A MX2023012605A MX2023012605A MX2023012605A MX 2023012605 A MX2023012605 A MX 2023012605A MX 2023012605 A MX2023012605 A MX 2023012605A MX 2023012605 A MX2023012605 A MX 2023012605A MX 2023012605 A MX2023012605 A MX 2023012605A
Authority
MX
Mexico
Prior art keywords
methods
preparation
nucleic acids
modified nucleic
therapeutic uses
Prior art date
Application number
MX2023012605A
Other languages
English (en)
Inventor
Ryan A Flynn
Brian Goodman
Ciaran Lawlor
Namita Bisaria
Richard D Cummings
Mohui Wei
Carolyn R Bertozzi
Original Assignee
Ganna Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganna Bio Inc filed Critical Ganna Bio Inc
Publication of MX2023012605A publication Critical patent/MX2023012605A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)

Abstract

La presente descripción se refiere a ácidos gliconucleicos, tales como glicoARN y glicoADN descritos en la presente. Se proporcionan composiciones y métodos relacionados con ácido ribonucleico glicosilado (glicoARN).
MX2023012605A 2021-04-23 2022-04-25 Acidos nucleicos modificados con glicano, metodos de preparacion y usos terapeuticos. MX2023012605A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163179065P 2021-04-23 2021-04-23
US202163188930P 2021-05-14 2021-05-14
US202163189492P 2021-05-17 2021-05-17
PCT/US2022/026117 WO2022226396A1 (en) 2021-04-23 2022-04-25 Glycan modified nucleic acids, methods of preparation, and therapeutic uses

Publications (1)

Publication Number Publication Date
MX2023012605A true MX2023012605A (es) 2024-02-23

Family

ID=81648838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012605A MX2023012605A (es) 2021-04-23 2022-04-25 Acidos nucleicos modificados con glicano, metodos de preparacion y usos terapeuticos.

Country Status (10)

Country Link
US (3) US11766481B2 (es)
EP (1) EP4326334A1 (es)
JP (1) JP2024514954A (es)
KR (1) KR20240028335A (es)
AU (1) AU2022262794A1 (es)
CA (1) CA3217717A1 (es)
IL (1) IL307885A (es)
MX (1) MX2023012605A (es)
TW (1) TW202304472A (es)
WO (1) WO2022226396A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114762694B (zh) * 2021-01-13 2023-07-14 中国人民解放军军事科学院军事医学研究院 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
WO2024086767A2 (en) * 2022-10-21 2024-04-25 Ganna Bio, Inc. Glycan conjugate compositions and methods
WO2025049634A1 (en) * 2023-08-29 2025-03-06 Ganna Bio, Inc. Glycan conjugate compositions and methods
WO2025049527A1 (en) * 2023-08-29 2025-03-06 The Medical College Of Wisconsin, Inc. Y-rna compositions and methods of using the same
WO2025079563A1 (ja) * 2023-10-13 2025-04-17 アークレイ株式会社 ５'末端アデニル化一本鎖ｄｎａの分解方法、３'アダプターの核酸へのライゲーション方法、ｎｇｓライブラリの調製方法、ｎｇｓライブラリ調製キット、及び核酸ライブラリ調製用３'アダプター
CN119162166B (zh) * 2024-11-21 2025-04-04 吉林大学 一种肿瘤glycoRNA的提纯筛选方法、系统及设备

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010296A1 (en) 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
JP5635412B2 (ja) 2007-12-04 2014-12-03 アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 標的化脂質
EP2580324A4 (en) * 2010-06-11 2013-11-27 Univ Brandeis PROCESS FOR THE DEVELOPMENT OF VACCINES BASED ON OLIGOSACCHARIDE OLIGONUCLEOTIDE CONJUGATES
MX346144B (es) 2010-12-17 2017-03-09 Arrowhead Res Corp * Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi.
BR112014004585A2 (pt) 2011-08-26 2017-06-13 Arrowhead Res Corp polímeros de poli(éster vinílico) para liberação de ácido nucleico in vivo
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
WO2015107115A1 (en) * 2014-01-15 2015-07-23 Basf Se Saccharide-modified nucleic acid molecules
WO2016100812A1 (en) 2014-12-19 2016-06-23 Moderna Therapeutics, Inc. Terminal modifications of polynucleotides
ES2969082T3 (es) 2015-09-17 2024-05-16 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
CA3011946A1 (en) 2016-03-07 2017-09-14 Arrowhead Pharmaceuticals, Inc. Targeting ligands for therapeutic compounds
JP7022687B2 (ja) * 2016-06-30 2022-02-18 協和キリン株式会社 核酸複合体
EP4218802A3 (en) 2016-07-01 2023-09-27 The Board of Trustees of the Leland Stanford Junior University Conjugates for targeted cell surface editing
KR102403408B1 (ko) 2016-09-02 2022-05-30 애로우헤드 파마슈티컬스 인코포레이티드 표적화 리간드
EP3704262B1 (en) 2017-10-30 2024-03-20 Georgia Tech Research Corporation Multiplexed analysis of materials for tissue delivery
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
WO2020072922A1 (en) 2018-10-05 2020-04-09 Verily Life Sciences Llc Barcoded nanoparticles for specific targeting in vivo
WO2020120442A2 (en) 2018-12-13 2020-06-18 Dna Script Direct oligonucleotide synthesis on cells and biomolecules
AU2020207935A1 (en) 2019-01-18 2021-08-26 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
CA3151622A1 (en) 2019-09-20 2021-03-25 The Trustees Of The University Of Pennsylvania Compositions and methods comprising ionizable lipid nanoparticles encapsulating barcoded mrna

Also Published As

Publication number Publication date
EP4326334A1 (en) 2024-02-28
US11766481B2 (en) 2023-09-26
CA3217717A1 (en) 2022-10-27
US20240115714A1 (en) 2024-04-11
WO2022226396A1 (en) 2022-10-27
AU2022262794A1 (en) 2023-11-02
AU2022262794A9 (en) 2023-11-16
IL307885A (en) 2023-12-01
US20240261420A1 (en) 2024-08-08
KR20240028335A (ko) 2024-03-05
TW202304472A (zh) 2023-02-01
US20220387607A1 (en) 2022-12-08
JP2024514954A (ja) 2024-04-03

Similar Documents

Publication Publication Date Title
MX2023012605A (es) Acidos nucleicos modificados con glicano, metodos de preparacion y usos terapeuticos.
WO2023283642A8 (en) Pan-human coronavirus concatemeric vaccines
WO2022221359A8 (en) Epstein-barr virus mrna vaccines
MX2022009280A (es) Vacunas de arn contra el coronavirus.
WO2021155243A8 (en) Respiratory virus immunizing compositions
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
WO2022271965A3 (en) Compositions and methods for improved protein translation from recombinant circular rnas
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
WO2007010401A3 (en) Glycosylated il-7, preparation and uses
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
HK1206761A1 (en) Nutritive fragments, proteins and methods
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
ZA202205000B (en) Cyclooctatetraene containing dyes and compositions
NZ742745A (en) Variants of chymosin with improved milk-clotting properties
IN2015DN03206A (es)
HK1206763A1 (en) Charged nutritive fragments, proteins and methods
AU2017329645A8 (en) Novel antibodies against Factor XI and uses thereof
WO2008033556A3 (en) High pressure treatment of proteins for reduced immunogenicity
PH12017502323B1 (en) Novel xylanase
WO2023010083A3 (en) Recombinant prenyltransferase polypeptides engineered for enhanced biosynthesis of cannabinoids
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
WO2007084488A3 (en) Adam10 and its uses related to infection
WO2021202443A8 (en) Compositions and methods for silencing dnajc15 gene expression
WO2020242719A3 (en) Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof
NZ629093A (en) Monoterpene glycosyltransferase originating from hop and method for using same